A new company financed by Bain Capital intends to stake a position in the sterile compounding market. QuVa Pharma has started by acquiring an FDA 503B registered compounding facility in Sugar Land, TX, from Helix. Terms of the deal were not disclosed. QuVa was founded by Stuart Hinchen, who is CEO, and Peter Jenkins, who is chief development officer. Both executives bring to QuVa Pharma the experience from time at JHP Pharmaceuticals and Mayne Pharma, the company said in a release. "With the support of Bain Capital Private Equity, we will be able to aggressively pursue an expansion strategy," Hinchen said in a statement. The FDA started the registration program for compounding pharmacies last year as part of the Drug Quality and Security Act. Release | More